NCT03393572View on ClinicalTrials.gov

Intraperitoneal Bupivacaine With Magnesium or Nalbuphine for Postoperative Pain Control in Laparoscopic Hysterectomy

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

June 5, 2018

Study Completion Date

June 15, 2018

Conditions
Anesthesia
Interventions
DRUG

Bupivacaine 0.25%

Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%

DRUG

Magnesium sulphate.

Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.

DRUG

nalbuphine

Patients will receive intraperitoneal 5 mg nalbuphine

Trial Locations (1)

11591

Marwa Elbeialy, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT03393572 - Intraperitoneal Bupivacaine With Magnesium or Nalbuphine for Postoperative Pain Control in Laparoscopic Hysterectomy | Biotech Hunter | Biotech Hunter